NO20006457L - Vaksine-indusert hepatitt B viral stamme og anvendelser derav - Google Patents

Vaksine-indusert hepatitt B viral stamme og anvendelser derav

Info

Publication number
NO20006457L
NO20006457L NO20006457A NO20006457A NO20006457L NO 20006457 L NO20006457 L NO 20006457L NO 20006457 A NO20006457 A NO 20006457A NO 20006457 A NO20006457 A NO 20006457A NO 20006457 L NO20006457 L NO 20006457L
Authority
NO
Norway
Prior art keywords
hepatitis
virus
major
surface antigen
amino acid
Prior art date
Application number
NO20006457A
Other languages
English (en)
Norwegian (no)
Other versions
NO20006457D0 (no
Inventor
Chong Jin Oon
Gek Keow Lim
Ai Lin Leong
Yi Zhao
Wei Ning Chen
Original Assignee
Government Republic Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Republic Singapore filed Critical Government Republic Singapore
Publication of NO20006457D0 publication Critical patent/NO20006457D0/no
Publication of NO20006457L publication Critical patent/NO20006457L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G01N33/5764—Hepatitis B surface antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
NO20006457A 1998-06-19 2000-12-18 Vaksine-indusert hepatitt B viral stamme og anvendelser derav NO20006457L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SG1998/000045 WO1999066047A1 (en) 1998-06-19 1998-06-19 A vaccine-induced hepatitis b viral strain and uses thereof

Publications (2)

Publication Number Publication Date
NO20006457D0 NO20006457D0 (no) 2000-12-18
NO20006457L true NO20006457L (no) 2001-02-16

Family

ID=20429861

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006457A NO20006457L (no) 1998-06-19 2000-12-18 Vaksine-indusert hepatitt B viral stamme og anvendelser derav

Country Status (22)

Country Link
US (2) US7038035B1 (is)
EP (1) EP1086232A1 (is)
JP (1) JP2002518013A (is)
KR (1) KR100498117B1 (is)
CN (1) CN1255540C (is)
AR (1) AR020092A1 (is)
AU (1) AU756858B2 (is)
BG (1) BG105065A (is)
BR (1) BR9815912A (is)
CA (1) CA2332173A1 (is)
HU (1) HUP0103258A3 (is)
IL (1) IL140363A0 (is)
IS (1) IS5777A (is)
MX (1) MXPA00012724A (is)
MY (1) MY135991A (is)
NO (1) NO20006457L (is)
NZ (1) NZ508892A (is)
PL (1) PL191312B1 (is)
TR (1) TR200003778T2 (is)
UA (1) UA73475C2 (is)
WO (1) WO1999066047A1 (is)
YU (1) YU80500A (is)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP967999A0 (en) * 1999-04-09 1999-05-06 North Western Health Care Network Viral variants
AUPQ810900A0 (en) 2000-06-09 2000-07-06 Austin and Repatriation Medical Centre, The Viral variants and methods of using same
CN100355777C (zh) * 2003-02-10 2007-12-19 文洪模 乙型肝炎病毒pre-S突变蛋白及其制备方法与应用
US20060057670A1 (en) * 2004-09-10 2006-03-16 The Chinese University Of Hong Kong Genomic markers of hepatitis B virus associated with hepatocellular carcinomas
ES2428630T3 (es) * 2004-09-22 2013-11-08 Advanced Life Science Institute, Inc. Método para detectar el antígeno s del virus de la hepatitis B
TW200643171A (en) * 2005-06-07 2006-12-16 Temasek Life Sciences Lab Ltd Porcine circovirus type 2 vaccines
CN101948933B (zh) * 2010-07-22 2013-04-03 中国人民解放军第三〇二医院 检测石蜡包埋肝组织乙型肝炎病毒cccDNA的试剂盒
CN101948932B (zh) * 2010-07-22 2013-04-03 中国人民解放军第三〇二医院 滚环扩增加跨缺口荧光定量PCR检测乙型肝炎病毒cccDNA试剂盒
RU2603729C2 (ru) * 2015-04-24 2016-11-27 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантная вакцина для профилактики вирусного гепатита в (варианты)
RU2586513C1 (ru) * 2015-04-24 2016-06-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ МУТАНТНОГО ПОВЕРХНОСТНОГО АНТИГЕНА ВИРУСА ГЕПАТИТА В (ВАРИАНТЫ)
HRP20241379T1 (hr) 2019-09-30 2024-12-20 Gilead Sciences, Inc. Cjepiva za hbv i postupci za liječenje hbv
CN113201051B (zh) * 2021-04-27 2022-08-02 复旦大学 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9007024D0 (en) * 1990-03-29 1990-05-30 Imperial College Novel vaccine
US5955089A (en) * 1993-04-20 1999-09-21 Uab Research Foundation Strain selection of pneumococcal surface proteins
GB9401987D0 (en) 1994-02-02 1994-03-30 Imperial College Modified nucleic acid
US5830759A (en) * 1994-08-18 1998-11-03 The Trustees Of Columbia University In The City Of New York Unique associated Kaposi's sarcoma virus sequences and uses thereof
US5980901A (en) 1996-09-18 1999-11-09 The Board Of Regents Of The University Of Texas System Viral defective interfering particles and uses thereof

Also Published As

Publication number Publication date
CN1304453A (zh) 2001-07-18
PL345203A1 (en) 2001-12-03
YU80500A (sh) 2004-05-12
AR020092A1 (es) 2002-04-10
AU7795098A (en) 2000-01-05
KR100498117B1 (ko) 2005-07-01
AU756858B2 (en) 2003-01-23
US20070026422A1 (en) 2007-02-01
WO1999066047A1 (en) 1999-12-23
US7038035B1 (en) 2006-05-02
HUP0103258A2 (hu) 2001-12-28
JP2002518013A (ja) 2002-06-25
BR9815912A (pt) 2002-02-05
PL191312B1 (pl) 2006-04-28
MXPA00012724A (es) 2003-02-10
IL140363A0 (en) 2002-02-10
HUP0103258A3 (en) 2003-10-28
NZ508892A (en) 2004-02-27
TR200003778T2 (tr) 2001-06-21
UA73475C2 (en) 2005-08-15
CN1255540C (zh) 2006-05-10
CA2332173A1 (en) 1999-12-23
BG105065A (en) 2001-09-28
NO20006457D0 (no) 2000-12-18
KR20010106128A (ko) 2001-11-29
MY135991A (en) 2008-07-31
EP1086232A1 (en) 2001-03-28
IS5777A (is) 2000-12-19

Similar Documents

Publication Publication Date Title
RU2280690C2 (ru) Рекомбинантные вирусы гриппа а
Donnelly et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus
Del Val et al. Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope
Geeraedts et al. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling
Hilleman Yeast recombinant hepatitis B vaccine
Nara et al. Neutralization of HIV‐1: a paradox of humoral proportions
Muster et al. Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus
Planz et al. Specific cytotoxic T cells eliminate cells producing neutralizing antibodies
Stoloff et al. Synthetic multi‐epitope peptides identified in silico induce protective immunity against multiple influenza serotypes
Ferko et al. Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice
US6420141B1 (en) Anti-HIV immunogens (toxoids), preparation methods and use for preventing and treating aids
Rajčáni et al. Current developments in viral DNA vaccines: shall they solve the unsolved?
CN107531761A (zh) 巨细胞病毒抗原及其用途
AU2001250352A1 (en) Recombinant influenza A viruses
Wang et al. The use of an E1-deleted, replication-defective adenovirus recombinant expressing the rabies virus glycoprotein for early vaccination of mice against rabies virus
WO2021207848A1 (en) Mers-cov vaccine
Bauer et al. Variants of two major T cell epitopes within the hepatitis B surface antigen are not recognized by specific T helper cells of vaccinated individuals
Norris et al. CD4+ T helper cells and the role they play in viral control
Jones et al. Efficient purification and rigorous characterisation of a recombinant gp120 for HIV vaccine studies
JP2003230396A (ja) gp350/220非スプライシング変異体
Shiraki et al. Construction of Oka varicella vaccine expressing human immunodeficiency virus env antigen
Cox et al. Immunization of common marmosets with Epstein‐Barr virus (EBV) envelope glycoprotein gp340: effect on viral shedding following EBV challenge
Kutinová et al. Immune response to vaccinia virus recombinants expressing glycoproteins gE, gB, gH, and gL of varicella-zoster virus
WO2022085648A1 (ja) 融合タンパク質及びワクチン
CN1733798B (zh) 乙型肝炎病毒表面l蛋白相关肽

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application